Table 4.

Laboratory results and clinical outcomes of patients with AIC

MT+, n = 25MT, n = 55P value
Coombs test n = 12 n = 28 .03 
IgG only 5 (42) 14 (50)  
IgG and complement 6 (50) 3 (11)  
Complement only 1 (10) 4 (14)  
Negative 0 (0) 7 (25)  
IgG, mg/dL 936 (687-1128) 1370 (1012-1800) .001 
Absolute lymphocyte count, ×103/μL 0.8 (0.5-1.7) 1.2 (0.7-2.52) .14 
Absolute neutrophil count, ×103/μL 4.3 (3.02-8.5) 3.3 (2.05-6.28) .09 
Nadir hemoglobin (g/dL) for AIHA and ES n = 10
6.3 (5.48-8.2) 
n = 20
6.1 (5.35-7.85) 
.70 
Nadir platelet (×103/μL) for ITP and ES n = 16
28.5 (8.5-95.50) 
n = 36
18 (2-49.8) 
.30 
Treatment requirement 19 (76) 48 (87) .48 
No. of lines of treatment n = 19
3 (1.5-3.5) 
n = 48
3 (2-4) 
.70 
Response    
CR 6/19 (32) 24/48 (50) .30 
Response 11/19 (58) 18/48 (38)  
No response 2/19 (11) 6/48 (12)  
Infection    
Overall 15 (60) 33 (59) 
Required hospitalization 6 (24) 12 (21) .78 
MT+, n = 25MT, n = 55P value
Coombs test n = 12 n = 28 .03 
IgG only 5 (42) 14 (50)  
IgG and complement 6 (50) 3 (11)  
Complement only 1 (10) 4 (14)  
Negative 0 (0) 7 (25)  
IgG, mg/dL 936 (687-1128) 1370 (1012-1800) .001 
Absolute lymphocyte count, ×103/μL 0.8 (0.5-1.7) 1.2 (0.7-2.52) .14 
Absolute neutrophil count, ×103/μL 4.3 (3.02-8.5) 3.3 (2.05-6.28) .09 
Nadir hemoglobin (g/dL) for AIHA and ES n = 10
6.3 (5.48-8.2) 
n = 20
6.1 (5.35-7.85) 
.70 
Nadir platelet (×103/μL) for ITP and ES n = 16
28.5 (8.5-95.50) 
n = 36
18 (2-49.8) 
.30 
Treatment requirement 19 (76) 48 (87) .48 
No. of lines of treatment n = 19
3 (1.5-3.5) 
n = 48
3 (2-4) 
.70 
Response    
CR 6/19 (32) 24/48 (50) .30 
Response 11/19 (58) 18/48 (38)  
No response 2/19 (11) 6/48 (12)  
Infection    
Overall 15 (60) 33 (59) 
Required hospitalization 6 (24) 12 (21) .78 

Data are presented as n (%) and median (interquartile range). Statistically significant results are set in bold.

or Create an Account

Close Modal
Close Modal